Announcements Trials
Browse Landscape

Phase

Phase 2 91Phase 1 24Phase 3 17Phase 1/2 13Phase 4 3Phase EARLY_PHASE1 2Phase 2/3 2Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostatic Neoplasms 1Pharmacogenetic Study 1

Interventions

Radiosurgery 45Magnetic Resonance Spectroscopy 41Standard of Care 27Radiotherapy 27Exercise 27Brachytherapy 21Early Intervention, Educational 20Surveys and Questionnaires 18Multiparametric Magnetic Resonance Imaging 17Magnetic Resonance Imaging 16Androgen Antagonists 16Blood Specimen Collection 15Interviews as Topic 14Radiotherapy, Intensity-Modulated 13Methods 13Therapeutics 12Psychiatric Rehabilitation 12Educational Status 12Biopsy 12Specimen Handling 10Resistance Training 10Prostatectomy 9Diet Therapy 9Counseling 9gallium 68 PSMA-11 8Radiation 8Proton Therapy 8Practice Guidelines as Topic 8High-Intensity Interval Training 7Electroporation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Prostatic Neoplasms × Abiraterone Acetate × Clear all
NCT01961843 2025-11-25

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Massachusetts General Hospital

Phase NA Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡